CXCR3 Axis: Role in Inflammatory Bowel Disease and its Therapeutic Implication
The DOI matches its Crossref record.
Abstract
There is a great need for new intervention and prevention strategies against Crohn's disease (CD), a chronic, relapsing tissue-destructive inflammatory bowel disease (IBD). Estimates indicate more than 1 million cases of IBD in the United States occur annually, with 50% involving CD. The clinical features of CD correlate with certain mouse models of colitis, including the spontaneous colitis observed in interleukin-10 deficient (IL-10(-/-)), senescence accelerated mice (SAMP1/Yit) and trinitrobenzene sulfonic acid (TNBS)-treated mice. Chemokines undoubtedly play a pivotal role in the regulation (i.e., initiation, maintenance, and suppression) of mucosal inflammation and tissue destruction. A number of key advances have led to greater understanding of the steps responsible for colitis and the roles played by chemokines. In fact, CXCR3 and the ligands for this chemokine receptor, monokine-induced by interferon-gamma (IFN-gamma) (MIG/CXCL9), IFN-gamma-inducible 10 kDa protein (IP-10/CXCL10), and IFN-gamma-inducible T cell alpha-chemoattractant (I-TAC/CXCL11) are differentially expressed at sites of colitis in IL-10(-/-) mice and in clinical cases of CD. While we have demonstrated that antibodies directed against CXCL10 could both prevent the onset and cure of pre-existing colitis in IL-10(-/-) mice, studies by other investigators have shown the efficacy of CXCR3 blockade to mitigate colitis and other inflammatory diseases. This review describes the hallmarks of IBD, CXCL9-11, and CXCR3 expression during murine colitis and IBD, gives an overview of the antagonist therapies targeting the CXCR3 axis, details current and pending bio-therapies for IBD, and discusses what is known about the cellular and CXCR3-mediated mechanisms of colitis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications
Liu, M., Guo, S., Hibbert, J. M., Jain, V., Singh, N., Wilson, N. O., & Stiles, J. K. (2011) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2011.06.001 · Cited by 751
Chemokine and cytokine levels in inflammatory bowel disease patients
Singh, U. P., Singh, N. P., Murphy, E. A., Price, R. L., Fayad, R., Nagarkatti, M., & Nagarkatti, P. S. (2016) · Cytokine · doi:10.1016/j.cyto.2015.10.008 · Cited by 316
Self-citationCXCR3 ligands in disease and therapy
Van Raemdonck, K., Van den Steen, P. E., Liekens, S., Van Damme, J., & Struyf, S. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.11.009 · Cited by 310
Integrated gut/liver microphysiological systems elucidates inflammatory inter‐tissue crosstalk
Chen, W. L. K., Edington, C., Suter, E., Yu, J., Velazquez, J. J., Velazquez, J. G., Shockley, M., Large, E. M., Venkataramanan, R., Hughes, D. J., et al. (2017) · Biotechnology and Bioengineering · doi:10.1002/bit.26370 · Cited by 172
Saha, S., Jing, X., Park, S. Y., Wang, S., Li, X., Gupta, D., & Dziarski, R. (2010) · Cell Host & Microbe · doi:10.1016/j.chom.2010.07.005 · Cited by 137
Metadata
- Authors
- Singh, U., Venkataraman, C., Singh, R., & Lillard Jr., J.
- Venue
- Endocrine‚ Metabolic & Immune Disorders-Drug Targets
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2007-06-01
- Volume
- 7
- Issue
- 2
- Pages
- 111-123
- ISSN
- 1871-5303 (ISSN-L)
- OpenAlex
- W2137936519
- Cited by
- 111
- References
- 0
- FWCI
- 4.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CXCR3 Axis: Role in Inflammatory Bowel Disease and its Therapeutic Implication. https://app.cochat.ai/papers/10.2174/187153007780832109
- The paper
- Singh, U., Venkataraman, C., Singh, R., & Lillard Jr., J. (2007). CXCR3 Axis: Role in Inflammatory Bowel Disease and its Therapeutic Implication. Endocrine‚ Metabolic & Immune Disorders-Drug Targets. https://doi.org/10.2174/187153007780832109
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.